The DOI matches its Crossref record; 127 of the 127 references it cites were found in a registry or an index.
Treatment of rheumatoid arthritis
Abstract
PURPOSE: Current and investigational treatments of rheumatoid arthritis (RA) are described. SUMMARY: The current therapies used to treat RA include nonsteroidal antiinflammatory drugs (NSAIDs), used for the management of pain and inflammation; disease-modifying antirheumatic drugs (DMARDs), used as first-line therapy for all newly diagnosed cases of RA; and biological-response modifiers, targeted agents that selectively inhibit specific molecules of the immune system. Glucocorticoids and other antirheumatic drugs are also used to treat RA. DMARDs include methotrexate, hydroxychloroquine, sulfasalazine, and leflunomide. NSAIDs and glucocorticoids are effective in controlling the pain, inflammation, and stiffness related to RA. Unlike NSAIDs, they slow clinical and radiographic progression of RA. The biological-response modifiers include infliximab, etanercept, and adalimumab (inhibitors of tumor necrosis factor [TNF]-alpha); anakinra, a recombinant inhibitor of interleukin-1; abatacept, the first costimulation blocker; and rituximab, a chimeric anti-CD20 monoclonal antibody. Investigational therapies for RA include anti-interleukin-6-receptor monoclonal antibodies, new TNF-alpha inhibitors (including one for oral administration), and antibodies against proteins critical for B-cell function and survival. Data accumulated in the past decade favor early aggressive therapy for patients suspected of having RA, including early referral to a rheumatologist, new diagnostic techniques, and aggressive therapy with DMARDs, glucocorticoids, and biological agents. The benefits of this approach have been demonstrated in clinical trials. CONCLUSION: Pharmacologic treatments of RA include NSAIDs, glucocorticoids, DMARDs, and biological agents. With an improved understanding of the pathophysiology of RA and the evidence from various clinical trials with the agents, early aggressive therapy with a combination of drugs or biological agents may be warranted for the effective treatment of RA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arnett, F. C., Edworthy, S. M., Bloch, D. A., Mcshane, D. J., Fries, J. F., Cooper, N. S., Healey, L. A., Kaplan, S. R., Liang, M. H., Luthra, H. S., et al. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310302 · Cited by 19,752
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,027
Silverstein, F. E., Faich, G., Goldstein, J. L., Simon, L. S., Pincus, T., Whelton, A., Makuch, R., Eisen, G., Agrawal, N. M., Stenson, W. F., et al. (2000) · JAMA · doi:10.1001/jama.284.10.1247 · Cited by 3,154
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
Lipsky, P. E., van der Heijde, D. M. F. M., St. Clair, E. W., Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Weisman, M., Emery, P., Feldmann, M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432202 · Cited by 2,996
American college of rheumatology preliminary definition of improvement in rheumatoid arthritis
Felson, D. T., Anderson, J. J., Boers, M., Bombardier, C., Furst, D., Goldsmith, C., Katz, L. M., Lightfoot, R., Paulus, H., Strand, V., et al. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380602 · Cited by 2,829
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519
Bongartz, T., Sutton, A. J., Sweeting, M. J., Buchan, I., Matteson, E. L., & Montori, V. (2006) · JAMA · doi:10.1001/jama.295.19.2275 · Cited by 2,468
Weinblatt, M. E., Kremer, J. M., Bankhurst, A. D., Bulpitt, K. J., Fleischmann, R. M., Fox, R. I., Jackson, C. G., Lange, M., & Burge, D. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901283400401 · Cited by 2,085
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Solomon, S. D., McMurray, J. J. V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., & Bertagnolli, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050405 · Cited by 2,052
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
Baert, F., Noman, M., Vermeire, S., Van Assche, G., D' Haens, G., Carbonez, A., & Rutgeerts, P. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020888 · Cited by 2,015
Weinblatt, M. E., Keystone, E. C., Furst, D. E., Moreland, L. W., Weisman, M. H., Birbara, C. A., Teoh, L. A., Fischkoff, S. A., & Chartash, E. K. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10697 · Cited by 1,757
Klareskog, L., van der Heijde, D., de Jager, J. P., Gough, A., Kalden, J., Malaise, M., Mola, E. M., Pavelka, K., Sany, J., Settas, L., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15640-7 · Cited by 1,751
A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis
Bathon, J. M., Martin, R. W., Fleischmann, R. M., Tesser, J. R., Schiff, M. H., Keystone, E. C., Genovese, M. C., Wasko, M. C., Moreland, L. W., Weaver, A. L., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432201 · Cited by 1,730
Moreland, L. W., Baumgartner, S. W., Schiff, M. H., Tindall, E. A., Fleischmann, R. M., Weaver, A. L., Ettlinger, R. E., Cohen, S., Koopman, W. J., Mohler, K., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707173370301 · Cited by 1,622
Goekoop‐Ruiterman, Y. P. M., De Vries‐Bouwstra, J. K., Allaart, C. F., Van Zeben, D., Kerstens, P. J. S. M., Hazes, J. M. W., Zwinderman, A. H., Ronday, H. K., Han, K. H., Westedt, M. L., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21405 · Cited by 1,460
Etanercept Therapy in Rheumatoid Arthritis: A Randomized, Controlled Trial
Moreland, L. W., Schiff, M. H., Baumgartner, S. W., Tindall, E. A., Fleischmann, R. M., Bulpitt, K. J., Weaver, A. L., Keystone, E. C., Furst, D. E., Mease, P. J., et al. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00004 · Cited by 1,379
Guidelines for the management of rheumatoid arthritis: 2002 Update
American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines (2002) · Arthritis & Rheumatism · doi:10.1002/art.10148 · Cited by 1,185
Keystone, E. C., Kavanaugh, A. F., Sharp, J. T., Tannenbaum, H., Hua, Y., Teoh, L. S., Fischkoff, S. A., & Chartash, E. K. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20217 · Cited by 1,172
St. Clair, E. W., van der Heijde, D. M. F. M., Smolen, J. S., Maini, R. N., Bathon, J. M., Emery, P., Keystone, E., Schiff, M., Kalden, J. R., Wang, B., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20568 · Cited by 1,143
Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study
Choi, H. K., Hernán, M. A., Seeger, J. D., Robins, J. M., & Wolfe, F. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08213-2 · Cited by 1,127
Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery
Nussmeier, N. A., Whelton, A. A., Brown, M. T., Langford, R. M., Hoeft, A., Parlow, J. L., Boyce, S. W., & Verburg, K. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050330 · Cited by 1,092
Guidelines for the management of rheumatoid arthritis: 2002 Update
Yood, R. A. (2002) · Cited by 1,090
Boers, M., Verhoeven, A. C., Markusse, H. M., van de Laar, M. A., Westhovens, R., van Denderen, J. C., van Zeben, D., Dijkmans, B. A., Peeters, A. J., Jacobs, P., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(97)01300-7 · Cited by 1,073
Kremer, J. M., Westhovens, R., Leon, M., Di Giorgio, E., Alten, R., Steinfeld, S., Russell, A., Dougados, M., Emery, P., Nuamah, I. F., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035075 · Cited by 1,058
Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α
Elliott, M. J., Maini, R. N., Feldmann, M., Long‐Fox, A., Charles, P., Katsikis, P., Brennan, F. M., Walker, J., Bijl, H., Ghrayeb, J., et al. (1993) · Arthritis & Rheumatism · doi:10.1002/art.1780361206 · Cited by 1,038
Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
Bresnihan, B., Alvaro-Gracia, J. M., Cobby, M., Doherty, M., Domljan, Z., Emery, P., Nuki, G., Pavelka, K., Rau, R., Rozman, B., et al. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199812)41:12<2196::aid-art15>3.0.co;2-2 · Cited by 981
Granulomatous Infectious Diseases Associated with Tumor Necrosis Factor Antagonists
Wallis, R. S., Broder, M. S., Wong, J. Y., Hanson, M. E., & Beenhouwer, D. O. (2004) · Clinical Infectious Diseases · doi:10.1086/383317 · Cited by 977
Graham, D. J., Campen, D., Hui, R., Spence, M., Cheetham, C., Levy, G., Shoor, S., & Ray, W. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17864-7 · Cited by 913
Möttönen, T., Hannonen, P., Leirisalo-Repo, M., Nissilä, M., Kautiainen, H., Korpela, M., Laasonen, L., Julkunen, H., Luukkainen, R., Vuori, K., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)08513-4 · Cited by 865
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis
Jüni, P., Nartey, L., Reichenbach, S., Sterchi, R., Dieppe, P. A., & Egger, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17514-4 · Cited by 846
The Effect of Glucocorticoids on Joint Destruction in Rheumatoid Arthritis
Kirwan, J. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199507203330302 · Cited by 817
Sharief, M. K., & Hentges, R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108153250704 · Cited by 809
Anti-inflammatory drugs and their mechanism of action
Vane, J. R., & Botting, R. M. (1998) · Inflammation Research · doi:10.1007/s000110050284 · Cited by 798
Nishimoto, N., Yoshizaki, K., Miyasaka, N., Yamamoto, K., Kawai, S., Takeuchi, T., Hashimoto, J., Azuma, J., & Kishimoto, T. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20303 · Cited by 788
Smolen, J. S., Kalden, J. R., Scott, D. L., Rozman, B., Kvien, T. K., Larsen, A., Loew-Friedrich, I., Oed, C., & Rosenburg, R. (1999) · The Lancet · doi:10.1016/s0140-6736(98)09403-3 · Cited by 771
Treatment of Active Rheumatoid Arthritis With Leflunomide Compared With Placebo and Methotrexate
Strand, V. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.21.2542 · Cited by 754
Horai, R., Saijo, S., Tanioka, H., Nakae, S., Sudo, K., Okahara, A., Ikuse, T., Asano, M., & Iwakura, Y. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.2.313 · Cited by 749
Genovese, M. C., Bathon, J. M., Martin, R. W., Fleischmann, R. M., Tesser, J. R., Schiff, M. H., Keystone, E. C., Wasko, M. C., Moreland, L. W., Weaver, A. L., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10308 · Cited by 733
Infections in patients with rheumatoid arthritis treated with biologic agents
Listing, J., Strangfeld, A., Kary, S., Rau, R., von Hinueber, U., Stoyanova‐Scholz, M., Gromnica‐Ihle, E., Antoni, C., Herzer, P., Kekow, J., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21386 · Cited by 681
Cronstein, B. N., Naime, D., & Ostad, E. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116884 · Cited by 679
Turesson, C., O'Fallon, W. M., Crowson, C. S., Gabriel, S. E., & Matteson, E. L. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.62.8.722 · Cited by 672
Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update
American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200107)44:7<1496::aid-art271>3.0.co;2-5 · Cited by 647
Cohen, S., Hurd, E., Cush, J., Schiff, M., Weinblatt, M. E., Moreland, L. W., Kremer, J., Bear, M. B., Rich, W. J., & McCabe, D. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10141 · Cited by 638
New Drugs for Rheumatoid Arthritis
Olsen, N. J., & Stein, C. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmra032906 · Cited by 626
Landewé, R. B. M., Boers, M., Verhoeven, A. C., Westhovens, R., van de Laar, M. A. F. J., Markusse, H. M., van Denderen, J. C., Westedt, M. L., Peeters, A. J., Dijkmans, B. A. C., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10083 · Cited by 612
Methotrexate for Rheumatoid Arthritis
Kremer, J. M., Alarcón, G. S., Lightfoot, R. W., Willkens, R. F., Furst, D. E., Williams, H. J., Dent, P. B., & Weinblatt, M. E. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370304 · Cited by 607
Hafezi-Moghadam, A., Simoncini, T., Yang, Z., Limbourg, F. P., Plumier, J.-C., Rebsamen, M. C., Hsieh, C.-M., Chui, D.-S., Thomas, K. L., Prorock, A. J., et al. (2002) · Nature Medicine · doi:10.1038/nm0502-473 · Cited by 594
Therapeutic Strategies for Rheumatoid Arthritis
O'Dell, J. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040226 · Cited by 588
Emery, P., Zeidler, H., Kvien, T. K., Guslandi, M., Naudin, R., Stead, H., Verburg, K. M., Isakson, P. C., Hubbard, R. C., & Geis, G. S. (1999) · The Lancet · doi:10.1016/s0140-6736(99)02332-6 · Cited by 543
Saag, K. G., Koehnke, R., Caldwell, J. R., Brasington, R., Burmeister, L. F., Zimmerman, B., Kohler, J. A., & Furst, D. E. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90131-7 · Cited by 540
Self-citationLow-Dose Methotrexate: A Mainstay in the Treatment of Rheumatoid Arthritis
Cronstein, B. N. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.3 · Cited by 535
Genovese, M. C., Cohen, S., Moreland, L., Lium, D., Robbins, S., Newmark, R., Bekker, P., & for the 20000223 Study Group (2004) · Arthritis & Rheumatism · doi:10.1002/art.20221 · Cited by 532
Choy, E. H. S., Isenberg, D. A., Garrood, T., Farrow, S., Ioannou, Y., Bird, H., Cheung, N., Williams, B., Hazleman, B., Price, R., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10623 · Cited by 526
Da Silva, J. A. P., Jacobs, J. W. G., Kirwan, J. R., Boers, M., Saag, K. G., Inês, L. B. S., de Koning, E. J. P., Buttgereit, F., Cutolo, M., Capell, H., et al. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.038638 · Cited by 522
Self-citationMaini, R. N., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Furst, D., Weisman, M. H., St.Clair, E. W., Keenan, G. F., van der Heijde, D., Marsters, P. A., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20159 · Cited by 514
COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease
Ray, W. A., Stein, C. M., Daugherty, J. R., Hall, K., Arbogast, P. G., & Griffin, M. R. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11131-7 · Cited by 503
Furst, D. E., Schiff, M. H., Fleischmann, R., Strand, V., Birbara, C. A., Compagnone, D., Fischkoff, S. A., & Chartash, E. (2003) · PubMed · Cited by 495
Farkouh, M. E., Kirshner, H., Harrington, R. A., Ruland, S., Verheugt, F. W., Schnitzer, T. J., Burmester, G. R., Mysler, E., Hochberg, M. C., Doherty, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16894-3 · Cited by 490
van Everdingen, A. A., Jacobs, J. W. G., Siewertsz van Reesema, D. R., & Bijlsma, J. W. J. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-1-200201010-00006 · Cited by 489
Emery, P., Breedveld, F. C., Lemmel, E. M., Kaltwasser, J. P., Dawes, P. T., Gömör, B., Van den Bosch, F., Nordström, D., Bjørneboe, O., Dahl, R., et al. (2000) · Rheumatology · doi:10.1093/rheumatology/39.6.655 · Cited by 472
Kremer, J. M., Dougados, M., Emery, P., Durez, P., Sibilia, J., Shergy, W., Steinfeld, S., Tindall, E., Becker, J., Li, T., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21201 · Cited by 444
Lee, J., Slifman, N. R., Gershon, S. K., Edwards, E. T., Schwieterman, W. D., Siegel, J. N., Wise, R. P., Brown, S. L., Udall, J. N., & Braun, M. M. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10583 · Cited by 443
Tetracyclines, molecular and clinical aspects
Chopra, I., Hawkey, P. M., & Hinton, M. (1992) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/29.3.245 · Cited by 421
Matherly, L. H., & Goldman, I. D. (2003) · Vitamins & Hormones · doi:10.1016/s0083-6729(03)01012-4 · Cited by 386
Anker, S. D., & Coats, A. J. S. (2002) · International Journal of Cardiology · doi:10.1016/s0167-5273(02)00470-9 · Cited by 367
Goodson, N. J., Wiles, N. J., Lunt, M., Barrett, E. M., Silman, A. J., & Symmons, D. P. M. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10419 · Cited by 366
De Bosscher, K., Schmitz, M. L., Vanden Berghe, W., Plaisance, S., Fiers, W., & Haegeman, G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.25.13504 · Cited by 363
The safety and efficacy of the use of methotrexate in long‐term therapy for rheumatoid arthritis
Kremer, J. M., & Lee, J. K. (1986) · Arthritis & Rheumatism · doi:10.1002/art.1780290702 · Cited by 360
Kremer, J. M., Genovese, M. C., Cannon, G. W., Caldwell, J. R., Cush, J. J., Furst, D. E., Luggen, M. E., Keystone, E., Weisman, M. H., Bensen, W. M., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-9-200211050-00007 · Cited by 353
Minocycline in Rheumatoid Arthritis: A 48-Week, Double-Blind, Placebo-Controlled Trial
Tilley, B. C., Alarcon, G. S., Heyse, S. P., Trentham, D. E., Neuner, R., Kaplan†, D. A., Clegg, D. O., Leisen, J. C. C., Buckley, L., Cooper, S. M., et al. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-2-199501150-00001 · Cited by 341
Invasive Pulmonary Aspergillosis Associated with Infliximab Therapy
(2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441415 · Cited by 330
Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy
Kroesen, S. (2003) · Rheumatology · doi:10.1093/rheumatology/keg263 · Cited by 328
The clinical significance of inhibition of renal prostaglandin synthesis
Patrono, C., & Dunn, M. J. (1987) · Kidney International · doi:10.1038/ki.1987.164 · Cited by 296
Clinical utility of the anti-CCP assay in patients with rheumatic diseases
Lee, D. M., & Schur, P. H. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.62.9.870 · Cited by 295
Gold Salts in the Treatment of Rheumatoid Arthritis: A Double-Blind Study
SIGLER, J. W., BLUHM, G. B., DUNCAN, H., SHARP, J. T., ENSIGN, D. C., & MCCRUM, W. R. (1974) · Annals of Internal Medicine · doi:10.7326/0003-4819-80-1-21 · Cited by 291
Weinblatt, M. E., Kremer, J. M., Coblyn, J. S., Maier, A. L., Helfgott, S. M., Morrell, M., Byrne, V. M., Kaymakcian, M. V., & Strand, V. (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199907)42:7<1322::aid-anr4>3.0.co;2-p · Cited by 286
Keystone, E. C., Schiff, M. H., Kremer, J. M., Kafka, S., Lovy, M., DeVries, T., & Burge, D. J. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20019 · Cited by 284
Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody.
Wendling, D., Racadot, E., & Wijdenes, J. (1993) · PubMed · Cited by 274
The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine
Mavrikakis, I., Sfikakis, P. P., Mavrikakis, E., Rougas, K., Nikolaou, A., Kostopoulos, C., & Mavrikakis, M. (2003) · Ophthalmology · doi:10.1016/s0161-6420(03)00409-3 · Cited by 256
Clinical Pharmacokinetics of Leflunomide
Rozman, B. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241060-00003 · Cited by 250
Felson, D. T., Anderson, J. J., & Meenan, R. F. (1992) · Arthritis & Rheumatism · doi:10.1002/art.1780351003 · Cited by 230
Quéméneur, L., Gerland, L.-M., Flacher, M., Ffrench, M., Revillard, J.-P., & Genestier, L. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.10.4986 · Cited by 229
Effects of Low-Dose Prednisone on Bone Metabolism
Ton, F. N., Gunawardene, S. C., Lee, H., & Neer, R. M. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.041125 · Cited by 223
Nuki, G., Bresnihan, B., Bear, M. B., & McCabe, D. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10578 · Cited by 222
Montesinos, M. C., Desai, A., Delano, D., Chen, J., Fink, J. S., Jacobson, M. A., & Cronstein, B. N. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10712 · Cited by 213
Cigarette smoking and the risk of rheumatoid arthritis among postmenopausal women:
Criswell, L. A., Merlino, L. A., Cerhan, J. R., Mikuls, T. R., Mudano, A. S., Burma, M., Folsom, A. R., & Saag, K. G. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01051-3 · Cited by 198
Self-citationThe anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites
Gadangi, P., Longaker, M., Naime, D., Levin, R. I., Recht, P. A., Montesinos, M. C., Buckley, M. T., Carlin, G., & Cronstein, B. N. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.5.1937 · Cited by 196
Phillips, D. C., Woollard, K. J., & Griffiths, H. R. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705054 · Cited by 183
Ortiz, Z., Shea, B., Suarez-Almazor, M. E., Moher, D., Wells, G. A., & Tugwell, P. (1998) · PubMed · Cited by 182
Simms, R. W., Kwoh, C. K., Anderson, L. G., Erlandson, D. M., Greene, J. M., Kelleher, M. E., O’Dell, J. R., Partridge, A. J., Roberts, W. N., Robbins, M. L., et al. (1996) · PubMed · Cited by 182
O'Dell, J. R., Haire, C. E., Palmer, W., Drymalski, W., Wees, S., Blakely, K., Churchill, M., Eckhoff, P. J., Weaver, A., Doud, D., et al. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400510 · Cited by 177
White, W. B., Faich, G., Borer, J. S., & Makuch, R. W. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00659-3 · Cited by 174
Minocycline in active rheumatoid arthritis
Kloppenburg, M., Breedveld, F. C., Terwiel, J. P. H., Mallee, C., & Dijkmans, B. A. C. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370505 · Cited by 172
Bas, S. (2002) · Rheumatology · doi:10.1093/rheumatology/41.7.809 · Cited by 170
Battistella, M. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.2.189 · Cited by 162
A randomized trial of hydroxychloroquine in early rheumatoid arthritis: The HERA study
The HERA Study Group* (1995) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)80399-4 · Cited by 158
The Pharmacokinetics of Etanercept in Healthy Volunteers
Korth-Bradley, J. M., Rubin, A. S., Hanna, R. K., et al. (2000) · Annals of Pharmacotherapy · doi:10.1345/aph.19126 · Cited by 155
LISSE, J. R., Perlman, M., Johansson, G. S., Shoemaker, J. R., Schechtman, J., Skalky, C. S., Dixon, M. E., Polis, A. B., Mollen, A., Geba, G. P., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-7-200310070-00005 · Cited by 149
Glucocorticoid-induced osteoporosis
Saag, K. G. (2003) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(02)00064-6 · Cited by 146
Self-citationA new method of scoring radiographic change in rheumatoid arthritis.
Rau, R., Wassenberg, S., Herborn, G., Stucki, G., & Gebler, A. (1998) · PubMed · Cited by 143
Weber, S. M., & Levitz, S. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.3.1534 · Cited by 129
Yanni, G., Nabil, M., Farahat, M. N. M. R., Poston, R. N., & Panayi, G. S. (1994) · Annals of the Rheumatic Diseases · doi:10.1136/ard.53.5.315 · Cited by 110
Verstappen, S. M. M., Jacobs, J. W. G., Bijlsma, J. W. J., Heurkens, A. H. M., van Booma-Frankfort, C., ter Borg, E. J., Hofman, D. M., & van der Veen, M. J. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11170 · Cited by 109
Major Histocompatibility Complex-Directed Susceptibility to Rheumatoid Arthritis
Nepom, G. T. (1998) · Advances in immunology · doi:10.1016/s0065-2776(08)60563-5 · Cited by 104
Hamdy, H., McKendry, R. J. R., Mierins, E., & Liver, J. A. (1987) · Arthritis & Rheumatism · doi:10.1002/art.1780300401 · Cited by 103
Khanna, D., Park, G. S., Paulus, H. E., Simpson, K. M., Elashoff, D. A., Cohen, S. B., Emery, P., Dorrier, C., & Furst, D. E. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21295 · Cited by 96
New therapies for rheumatoid arthritis
Goldblatt, F., & Isenberg, D. A. (2005) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2005.02744.x · Cited by 95
Kremer, J. M. (1999) · Seminars in Arthritis and Rheumatism · doi:10.1016/s0049-0172(99)80034-1 · Cited by 93
The early history of antirheumatic drugs
Rodnan, G. P., & Benedek, T. G. (1970) · Arthritis & Rheumatism · doi:10.1002/art.1780130207 · Cited by 91
How useful is the rheumatoid factor? An analysis of sensitivity, specificity, and predictive value
Shmerling, R. H. (1992) · Archives of Internal Medicine · doi:10.1001/archinte.152.12.2417 · Cited by 90
Inhibition of nuclear factor kappa B and induction of apoptosis in T‐lymphocytes by sulfasalazine
Liptay, S., Bachem, M. G., Häcker, G. A., Adler, G., Debatin, K., & Schmid, R. M. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702937 · Cited by 86
Listeria Meningitis After Treatment With Infliximab
Kamath, B. M., Mamula, P., Baldassano, R. N., et al. (2002) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/00005176-200204000-00018 · Cited by 86
How to prevent steroid induced osteoporosis
Sambrook, P. N. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.018556 · Cited by 78
Selective Cyclooxygenase-2 Inhibition and Cardiovascular Effects
Shaya, F. T. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.2.181 · Cited by 67
Refractory Nephrotic Syndrome in Lupus Nephritis: Favorable Response to Indomethacin Therapy
Espinoza, L. R., Jara, L. J., Martínez-Osuna, P., Silveira, L. H., Cuellar, M. L., & Seleznick, M. J. (1993) · Lupus · doi:10.1177/096120339300200103 · Cited by 61
Paternal and maternal exposure to leflunomide: pregnancy and neonatal outcome
Santis, M. D., Straface, G., Cavaliere, A. F., Carducci, B., & Caruso, A. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.030254 · Cited by 58
Sany, J., Kaiser, M. J., Jorgensen, C., et al. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.037499 · Cited by 52
Bouvy, M. L., Heerdink, E. R., Hoes, A. W., & Leufkens, H. G. M. (2003) · Drug Safety · doi:10.2165/00002018-200326130-00006 · Cited by 40
Mattey, D. L., Dawes, P. T., Fisher, J., Brownfield, A., Thomson, W., Hajeer, A. H., & Ollier, W. (2002) · PubMed · Cited by 35
Prevention of Glucocorticoid-induced Osteoporosis
Saag, K. G. (2004) · Southern Medical Journal · doi:10.1097/00007611-200406000-00008 · Cited by 21
Self-citationA signal achievement in the treatment of arthritis
Cron, R. Q. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21206 · Cited by 21
Carlin, G., Djursäter, R., & SMEDEGÅRD, G. (1992) · Annals of the Rheumatic Diseases · doi:10.1136/ard.51.11.1230 · Cited by 21
Digging for data from the COX-2 trials.
McCormack, J. P., & Rangno, R. (2002) · Europe PMC (PubMed Central) · Cited by 21
Ho (2001) · Pure Amsterdam UMC · doi:10.1002/1529-0131(200110)44:10 · Cited by 3
Komuro (2001) · doi:10.1002/1529-0131(200112)44:12
Cited by
Genovese, M. C., McKay, J. D., Nasonov, E. L., Mysler, E. F., da Silva, N. A., Alecock, E., Woodworth, T., & Gomez‐Reino, J. J. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23940 · Cited by 855
Jones, G., Sebba, A., Gu, J., Lowenstein, M. B., Calvo, A., Gomez-Reino, J. J., Siri, D. A., Tomšič, M., Alecock, E., Woodworth, T., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.105197 · Cited by 797
Combe, B., Landewe, R., Lukas, C., Bolosiu, H. D., Breedveld, F., Dougados, M., Emery, P., Ferraccioli, G., Hazes, J. M. W., Klareskog, L., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.044354 · Cited by 786
Emery, P., Breedveld, F. C., Dougados, M., Kalden, J. R., Schiff, M. H., & Smolen, J. S. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.4.290 · Cited by 445
Strategies toward rheumatoid arthritis therapy; the old and the new
Abbasi, M., Mousavi, M. J., Jamalzehi, S., Alimohammadi, R., Bezvan, M. H., Mohammadi, H., & Aslani, S. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27860 · Cited by 443
Metadata
- Authors
- Gaffo, A., Saag, K. G., & Curtis, J. R.
- Venue
- American Journal of Health-System Pharmacy
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-12-15
- Volume
- 63
- Issue
- 24
- Pages
- 2451-2465
- ISSN
- 1079-2082 (ISSN-L)
- 1535-2900
- OpenAlex
- W2162083117
- Cited by
- 266
- References
- 127
- FWCI
- 10.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.